Nov 28 (Reuters) - SpringWorks Therapeutics' drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of $29,000 for a 30-day supply, the company said on a conference call on Tuesday.

The U.S. health regulator on Monday approved the monotherapy branded as Ogsiveo, making it the first approved treatment for desmoid tumors, which are abnormal growths that occur in connective tissues and are associated with a high rate of recurrence.

(Reporting by Pratik Jain in Bengaluru; Editing by Shilpi Majumdar)